See more : T&R Biofab Co., Ltd. (246710.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of CV Sciences, Inc. (CVSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CV Sciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Ficha Inc. (4052.T) Income Statement Analysis – Financial Results
- Radial Research Corp. (RAD.CN) Income Statement Analysis – Financial Results
- Telenet Group Holding NV (TLGHF) Income Statement Analysis – Financial Results
- SMIT Holdings Limited (2239.HK) Income Statement Analysis – Financial Results
- Uzin Utz AG (UZU.DE) Income Statement Analysis – Financial Results
CV Sciences, Inc. (CVSI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cvsciences.com
About CV Sciences, Inc.
CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.00M | 16.21M | 20.05M | 24.43M | 53.70M | 48.24M | 20.68M | 11.06M | 11.53M | 10.19M | 2.15M | 0.00 | 0.00 |
| Cost of Revenue | 8.92M | 10.66M | 11.43M | 13.42M | 18.61M | 14.37M | 6.19M | 4.06M | 4.42M | 4.39M | 880.47K | 0.00 | 0.00 |
| Gross Profit | 7.09M | 5.55M | 8.62M | 11.01M | 35.09M | 33.88M | 14.49M | 7.00M | 7.11M | 5.80M | 1.27M | 0.00 | 0.00 |
| Gross Profit Ratio | 44.27% | 34.25% | 42.98% | 45.07% | 65.35% | 70.22% | 70.06% | 63.27% | 61.65% | 56.95% | 59.13% | 0.00% | 0.00% |
| Research & Development | 151.00K | 307.00K | 1.19M | 2.94M | 5.88M | 1.89M | 724.33K | 1.16M | 1.32M | 999.28K | 524.48K | 0.00 | 0.00 |
| General & Administrative | 6.55M | 3.89M | 13.93M | 19.36M | 34.39M | 21.75M | 16.25M | 13.13M | 17.75M | 13.36M | 2.37M | 0.00 | 88.09K |
| Selling & Marketing | 2.94M | 8.20M | 11.95M | 11.30M | 12.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.49M | 12.09M | 25.88M | 30.66M | 46.45M | 21.75M | 16.25M | 13.13M | 17.75M | 13.36M | 2.37M | 43.02K | 88.09K |
| Other Expenses | -5.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -12.27K | -8.55K | -73.21K | -34.82K | 0.00 | 43.02K | 0.00 |
| Operating Expenses | 3.73M | 12.40M | 27.06M | 33.60M | 52.33M | 23.63M | 16.98M | 13.91M | 19.07M | 14.36M | 2.89M | 43.02K | 88.09K |
| Cost & Expenses | 12.64M | 23.05M | 38.49M | 47.02M | 70.94M | 38.00M | 23.17M | 17.97M | 23.50M | 18.74M | 3.77M | 43.02K | 88.09K |
| Interest Income | 0.00 | 1.54M | 140.00K | 9.00K | 15.00K | 0.00 | 2.00 | 27.66K | 18.29K | 30.70K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.54M | 140.00K | 9.00K | 0.00 | 153.00K | 506.38K | 1.09M | 968.62K | 615.34K | 372.11K | 2.59K | 2.09K |
| Depreciation & Amortization | 235.00K | 1.06M | 1.50M | 1.47M | 1.53M | 519.00K | 182.00K | 1.05M | 1.01M | 933.60K | 767.25K | 43.02K | 0.00 |
| EBITDA | 3.85M | -5.66M | -14.00M | -21.72M | -15.69M | 10.77M | -4.69M | -12.00M | -10.25M | 236.99K | -1.16M | -2.59K | -88.09K |
| EBITDA Ratio | 24.03% | -36.13% | -86.26% | -88.91% | -30.77% | 22.32% | -11.21% | -52.80% | -95.49% | -75.19% | -39.46% | 0.00% | 0.00% |
| Operating Income | 3.36M | -6.85M | -18.45M | -22.59M | -17.24M | 10.25M | -4.86M | -13.07M | -11.21M | -8.55M | -1.62M | -43.02K | -88.09K |
| Operating Income Ratio | 20.99% | -42.25% | -92.01% | -92.48% | -32.11% | 21.24% | -23.50% | -118.20% | -97.23% | -83.93% | -75.08% | 0.00% | 0.00% |
| Total Other Income/Expenses | -264.00K | -1.41M | 2.81M | -9.00K | 15.00K | -153.00K | -519.00K | -1.07M | -1.02M | 7.24M | -682.86K | -2.59K | -2.09K |
| Income Before Tax | 3.10M | -8.26M | -15.64M | -22.60M | -17.23M | 10.09M | -5.38M | -14.14M | -12.23M | -1.31M | -2.30M | -45.61K | -90.18K |
| Income Before Tax Ratio | 19.35% | -50.98% | -78.02% | -92.52% | -32.08% | 20.92% | -26.01% | -127.85% | -106.10% | -12.87% | -106.78% | 0.00% | 0.00% |
| Income Tax Expense | -6.00K | -47.00K | -87.00K | -317.00K | -615.00K | 93.00K | -481.50K | 1.08M | 895.40K | 541.98K | 372.11K | -43.02K | 0.00 |
| Net Income | 3.10M | -8.21M | -15.55M | -22.28M | -16.61M | 10.00M | -4.90M | -14.14M | -12.23M | -1.31M | -2.30M | -45.61K | -90.18K |
| Net Income Ratio | 19.38% | -50.69% | -77.58% | -91.22% | -30.93% | 20.73% | -23.68% | -127.85% | -106.10% | -12.87% | -106.78% | 0.00% | 0.00% |
| EPS | 0.02 | -0.06 | -0.14 | -0.22 | -0.17 | 0.09 | -0.06 | -0.27 | -0.35 | -0.04 | -0.23 | -0.01 | -0.01 |
| EPS Diluted | 0.02 | -0.06 | -0.14 | -0.22 | -0.17 | 0.09 | -0.06 | -0.27 | -0.35 | -0.04 | -0.23 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 153.95M | 138.03M | 107.82M | 99.91M | 97.86M | 111.12M | 80.43M | 52.66M | 35.14M | 31.58M | 9.88M | 7.00M | 6.97M |
| Weighted Avg Shares Out (Dil) | 153.96M | 138.03M | 107.82M | 99.91M | 97.86M | 114.47M | 80.43M | 52.66M | 35.14M | 31.58M | 9.88M | 7.00M | 6.97M |
CV Sciences, Inc. (CVSI) Reports Q4 Loss, Lags Revenue Estimates
CV Sciences, Inc. Reports Fiscal Year-End 2020 Financial Results
A Preview Of CV Sciences's Earnings
Will CV Sciences, Inc. (CVSI) Report Negative Q4 Earnings? What You Should Know
CV Sciences, Inc. Receives Nutritional Outlook's 2020 Best of the Industry Award
CV Sciences Inc's (CVSI) CEO Joe Dowling on Q3 2020 Results - Earnings Call Transcript
CV Sciences, Inc. Announces Launch of PlusCBD™ Pet Product Line
Source: https://incomestatements.info
Category: Stock Reports